Showing 4801-4810 of 5646 results for "".
- Eyenuk Announces FDA Clearance for EyeArt Autonomous AI System for Diabetic Retinopathy Screeninghttps://modernod.com/news/eyenuk-announces-fda-clearance-for-eyeart-autonomous-ai-system-for-diabetic-retinopathy-screening/2478123/Eyenuk announced it has received 510(k) clearance by the FDA to market its EyeArt autonomous AI System for diabetic retinopathy. EyeArt is indicated for use by health care providers to automatically detect more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopa
- Eli Lilly Starts Late-Stage Study of Neutralizing Antibody Against SARS-CoV-2 in Nursing Homeshttps://modernod.com/news/eli-lilly-starts-late-stage-study-of-neutralizing-antibody-against-sars-cov-2-in-nursing-homes/2478118/Eli Lilly announced the initiation of a phase 3 study investigating whether its antibody-based drug LY-CoV555 can help reduce the rate of SARS-CoV-2 infection and COVID-19 in long-term care facilities in the US. The company is developing the neutralizing IgG1 antibody, which
- Regenxbio Announces Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd-2/2478113/Regenxbio reported positive 1 year data from patients in Cohorts 4 and 5 of the phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). The company plans to initiate a pivotal program for subretinal delivery of RGX-314 in patients with wet AMD by the end of 20
- Cardio Risk Increases With Diabetic Retinopathy Progressionhttps://modernod.com/news/cardio-risk-increases-with-diabetic-retinopathy-progression/2478116/The risk for heart attack, stroke, and even death increases as the severity of diabetic retinopathy increases. Severe retinopathy is linked to a doubling of the risk for cerebrovascular accident or myocardial infarction, results from a new study show, as
- Can You Get COVID-19 Through Your Eyes? Possibly.https://modernod.com/news/can-you-get-covid-19-through-your-eyes-possibly/2478112/We know that the coronavirus can enter the body through the nose and mouth — hence the constant recommendations from doctors to wear face coverings and practice social distancing. But what abou
- Oxurion Appoints Grace Chang, MD, PhD, as Chief Medical Officerhttps://modernod.com/news/oxurion-appoints-grace-chang-md-phd-as-chief-medical-officer/2478109/Oxurion NV announced the appointment of Grace Chang, MD, PhD, as the company’s Chief Medical Officer, effective August 1, 2020. Dr. Chang is a board-certified ophthalmologist and practicing vitreoretinal surgeon with deep expertise in ophthalmic drug research and development. She will be r
- The Vision Council Releases 2019 Vision Watch Cataract Reporthttps://modernod.com/news/the-vision-council-releases-2019-vision-watch-cataract-report/2478110/The Vision Council recently released the results of the 2019 VisionWatch Cataract Report. Conducted in December 2019, the study measures changes in consumer behavior related to vision and vision correction after undergoing cataract surgery. The intent of the study was to explore how cataract surg
- ReFocus Eye Health Acquires OptiCare Eye Health & Vision Centershttps://modernod.com/news/refocus-eye-health-acquires-opticare-eye-health-vision-centers/2478105/ReFocus Eye Health has announced the acquisition of OptiCare Eye Health & Vision Centers. Terms of the deal were not disclosed. “We couldn’t be more excited about the surgeons and staff of OptiCare becoming part of the ReFocus family,”
- MicroOptx Completes Patient Enrollment in Initial Phase of US Pivotal Trial for the Beacon Aqueous Microshunthttps://modernod.com/news/microoptx-completes-patient-enrollment-in-initial-phase-of-us-pivotal-trial-for-the-beacon-aqueous-microshunt/2478098/MicroOptx announced the completion of enrollment in the initial phase of the Beacon Study. This is the FDA investigational device exemption (IDE) clinical trial of the Beacon Aqueous Microshunt. Study participants treated during the initial phase of the interventional, single-arm, open label, mul
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremiahttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-4d-110-by-intravitreal-injection-for-the-treatment-of-choroideremia/2478092/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1 clinical trial of 4D-110, a Roche-licensed product candidate, delivered by a single intravitreal injection for Choroideremia. Choroideremia is a blinding and currently untreatable X-linked inher